Vischer advised Oculis SA on the deal, while Walder Wyss advised Hyfinity Investments. Oculis S.A., a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
